[go: up one dir, main page]

ES2639863B1 - Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato - Google Patents

Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato Download PDF

Info

Publication number
ES2639863B1
ES2639863B1 ES201730326A ES201730326A ES2639863B1 ES 2639863 B1 ES2639863 B1 ES 2639863B1 ES 201730326 A ES201730326 A ES 201730326A ES 201730326 A ES201730326 A ES 201730326A ES 2639863 B1 ES2639863 B1 ES 2639863B1
Authority
ES
Spain
Prior art keywords
mmol
oxalate
acid
treatment
salicylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201730326A
Other languages
English (en)
Spanish (es)
Other versions
ES2639863A1 (es
Inventor
Mónica DÍAZ GAVILÁN
José Antonio GÓMEZ VIDAL
María Dolores MOYA GARZÓN
Eduardo SALIDO RUIZ
Cristina MARTÍN HIGUERAS
Miguel Xavier FERNANDES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Granada
Universidad de La Laguna
Original Assignee
Universidad de Granada
Universidad de La Laguna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Granada, Universidad de La Laguna filed Critical Universidad de Granada
Priority to ES201730326A priority Critical patent/ES2639863B1/es
Publication of ES2639863A1 publication Critical patent/ES2639863A1/es
Priority to US16/492,750 priority patent/US20200197418A1/en
Priority to EP18764805.0A priority patent/EP3593803A4/fr
Priority to PCT/ES2018/070184 priority patent/WO2018162785A2/fr
Application granted granted Critical
Publication of ES2639863B1 publication Critical patent/ES2639863B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES201730326A 2017-03-10 2017-03-10 Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato Active ES2639863B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201730326A ES2639863B1 (es) 2017-03-10 2017-03-10 Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato
US16/492,750 US20200197418A1 (en) 2017-03-10 2018-03-12 Compounds for the treatment of diseases caused by oxalate accumulation
EP18764805.0A EP3593803A4 (fr) 2017-03-10 2018-03-12 Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
PCT/ES2018/070184 WO2018162785A2 (fr) 2017-03-10 2018-03-12 Composés destinés au traitement de maladies causées par l'accumulation d'oxalate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201730326A ES2639863B1 (es) 2017-03-10 2017-03-10 Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato

Publications (2)

Publication Number Publication Date
ES2639863A1 ES2639863A1 (es) 2017-10-30
ES2639863B1 true ES2639863B1 (es) 2018-09-20

Family

ID=60151157

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201730326A Active ES2639863B1 (es) 2017-03-10 2017-03-10 Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato

Country Status (4)

Country Link
US (1) US20200197418A1 (fr)
EP (1) EP3593803A4 (fr)
ES (1) ES2639863B1 (fr)
WO (1) WO2018162785A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019263176B2 (en) * 2018-04-30 2025-02-27 The Trustees Of Indiana University Compounds for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease
CN109293606B (zh) * 2018-11-20 2022-07-12 西华大学 2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途
CN109748789A (zh) * 2018-12-26 2019-05-14 中国药科大学 水杨酸类化合物及其医药用途
CN110934867B (zh) * 2019-12-25 2022-10-21 南方医科大学 Hao1抑制剂在制备抑制肿瘤肺转移前微环境形成及防治肿瘤肺转移的药物中的应用
WO2022035805A1 (fr) * 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. 1,2,4-oxadiazoles substitués utilisés en tant qu'inhibiteurs de petites molécules de la protéase 28 spécifique de l'ubiquitine
WO2024182489A1 (fr) * 2023-02-28 2024-09-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions et leurs procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558641A (en) * 1967-10-06 1971-01-26 Merck & Co Inc Certain pyridyl salicylic acid derivatives
JPH111464A (ja) * 1997-06-13 1999-01-06 Mitsui Chem Inc ジカルボン酸類化合物及びその製造方法
WO2006047162A2 (fr) * 2004-10-21 2006-05-04 The Burnham Institute Compositions et procedes de traitement de maladies causees par l'infection yersinia spp
RU2515968C2 (ru) * 2007-04-11 2014-05-20 Киссеи Фармасьютикал Ко., Лтд. 5-членное гетероциклическое соединение и его применение для лекарственных целей
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2017036404A1 (fr) * 2015-09-02 2017-03-09 Sunshine Lake Pharma Co., Ltd. Dérivés de cycle (hétéro) aromatique substitués par carboxy et procédés de préparation et utilisations associés

Also Published As

Publication number Publication date
EP3593803A4 (fr) 2020-04-08
WO2018162785A3 (fr) 2018-11-08
WO2018162785A2 (fr) 2018-09-13
US20200197418A1 (en) 2020-06-25
EP3593803A2 (fr) 2020-01-15
ES2639863A1 (es) 2017-10-30

Similar Documents

Publication Publication Date Title
ES2639863B1 (es) Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato
ES2864707T3 (es) Compuestos y usos de los mismos para la modulación de la hemoglobina
ES2640003T3 (es) Productos terapéuticos derivados de éter diglicidílico y métodos para su uso
ES2751922T3 (es) Donadores de nitroxilo con índice terapéutico mejorado
AU2013202373B2 (en) Proteasome activity enhancing compounds
AU2013202373A1 (en) Proteasome activity enhancing compounds
AU2013202368A1 (en) Proteasome activity modulating compounds
WO2013112706A1 (fr) Composés permettant de moduler l'activité de protéasome
CN104010501A (zh) 含src同源区2蛋白酪胺酸磷酸酶-1增效剂及其治疗方法
JP2024112835A (ja) プロテアソーム活性増強化合物
CN102336790B (zh) 一氧化氮供体型虎杖苷衍生物、制备方法及医药用途
JP6890132B2 (ja) 抗ウイルス用ウリジン類ホスホラミド、その調製方法およびその医薬における使用
CN111728962B (zh) 白藜芦醇衍生物及其抗纤维化的医药用途
Zhu et al. Design, synthesis and triglyceride-lowering activity of tricyclic matrine derivatives for the intervention of non-alcoholic fatty liver disease
CN107118250A (zh) 一种no供体型齐墩果酸衍生物及其制备方法和用途
ES2386550T3 (es) Derivados de piridazinilamina, el uso de los mismos en la preparación de inhibidores de picornavirus
CN112574172B (zh) 一种没食子酸硫化氢衍生物及其制备方法及医药用途
WO2023064368A1 (fr) Nouveaux dérivés de rhodanine et leurs utilisations
CN104341362B (zh) 三氮唑磺酰丙二酸类化合物、其制备方法及用途
EP4585216A1 (fr) Composés hétérocycliques pour le traitement de la stéatose hépatique
CN104262276B (zh) 含卤代苯的四氮唑乙酸类化合物、其制备方法及用途
CN118955491A (zh) 一类新型噻唑类hsd17b13抑制剂、其制备方法及其作为药物的用途
WO2022159566A1 (fr) Benzènesulfonamides comme agonistes de trap1 pour le traitement d'une fibrose d'organe
CN105193793A (zh) 组合物及其在抗急性肾衰药物中的应用
CN104370841A (zh) 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2639863

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20180920